CURRICULUM VITAE University of Colorado School …...2014-2016 Associate Professor of Medicine...

CURRICULUM VITAE University of Colorado

School of Medicine

Personal History:

Name in Full Tomer Martin Mark, M.D., M.Sc. Current Position Associate Professor of Medicine Business Address University of Colorado

Anschutz Medical Campus Anschutz Cancer Pavilion 1665 Aurora Court, MS F754

Aurora, CO 80045

Education: University Yale University, New Haven, CT, B.S. cum laude Molecular Biophysics and Biochemistry, 1998 Medical School State University of New York at Stony Brook Stony Brook, NY, M.D. with Recognition in Research, 2002 Internship Beth Israel Deaconess Medical Center Boston, MA, Internal Medicine, 2002-2003 Residency Beth Israel Deaconess Medical Center Boston, MA, Internal Medicine, 2003-2005 Fellowship New York Presbyterian Hospital/Weill Cornell Medical Center

Department of Medicine, Division of Hematology and Medical Oncology, 2005-2008

Graduate School Cornell University School of Graduate Sciences, New York, NY, Masters in Clinical Investigation, 2010

Colorado Clinical and Translational Science Institute: Leadership for Innovative Team

Science Program, graduated 4/2018 Academic Appointments:

Assistant Professor of Medicine New York Presbyterian Hospital / Weill Cornell Medical Center, New York, NY

2008-2014

Tomer Martin Mark, MD, MSc Curriculum Vitae

2

Associate Professor of Clinical Medicine

New York Presbyterian Hospital / Weill Cornell Medical Center, New York, NY

2014-2016

Associate Professor of Medicine

University of Colorado, Aurora, CO

2016-present

Hospital and Other Professional Positions: Hematology Consultant, Hospital for Special Surgery, New York, NY, July 2008 -June 2016 Honors and Awards: Fellowship 1st Place, Department of Medicine Fellows Award, 2007 Hermione Foundation Sponsored Fellowship Grant, 2007 Post-Graduate: Endowed Assistant Professorship - Morton Coleman Assistant

Professor in Multiple Myeloma, 2008 American Society of Hematology Clinical Research Training

Institute Award, 2008 Clinical and Translational Science Center K30 Grant Recipient,

2008 Multiple Myeloma Research Foundation Laugh for Life, 10th

Anniversary, Honorary Committee Member, 2012-2014 Named as “Super Doctors Rising Star” for New York, 2015 Professional Memberships:

American Society of Hematology, 2005 – present American Society of Clinical Oncology, 2005 – 2018 International Multiple Myeloma Society, 2008 – present

Major Committee and Service Responsibilities: International: Member of the International Multiple Myeloma Working Group, 2014-present

Center for International Blood and Marrow Research, Plasma Cell Disorders Working Group Co-Chairman, elected term: 2014-2019


3

National:

Lymphoma and Myeloma Satellite Symposium – New York, NY: Chairman, Myeloma Section, 2007 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY, Session Moderator: Clinical Pathology and Myeloma, 2009 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY, Session Moderator: Bench to Bedside, 2010

Founding Member of Tri-State Transplant Consortium, 2011 (including New York, Connecticut, and New Jersey), 2011 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY, Session Moderator: Special Considerations in Multiple Myeloma, 2013 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY, Session Moderator: Myeloma Treatment, 2015

Lymphoma and Myeloma: An International Congress of Hematologic Malignancies New York, NY, Session Moderator: Myeloma Treatment, 2016

American Society of Hematology, Multiple Myeloma Scientific Abstract Review Committee Member and Oral Session Moderator, 2009 American Society of Blood and Marrow Transplantation: Discussion leader for ASBMT Clinical Case Forum, Myeloma and Amyloidosis. 2019-present.

School of Medicine: Member Weill Cornell Medical College Clinical Study Evaluation Committee, 2014-2016 Member of the Data Safety Monitoring Board at Weill Cornell Medical College, 2010-2014 Associate Director of the Weill Cornell Multiple Myeloma Center, 2013-2016 Patient visit year, 4 myeloma specialists, 2 medical extenders, 2 Research RNs, 1 Research Associate. Administrative staff: 4, medical assistants: 3, Faculty practice manager: 1. Outpatient visits in 2014: 6308 New Visits in 2014: 170, Established 6,138 Inpatient visit in 2014: 2799 Chemotherapy visits in 2014: 7514


4

Chairman of Cancer Study Data Safety Monitoring Board at Weill Cornell Medical College, 2015-2016 Member, University of Colorado Anschutz Data Safety Monitoring Committee 1/2017 – present

Hospital:

Outpatient Hematology Attending for the Plasma Cell Disorders Clinic, New York Presbyterian Hospital – Weill Cornell Medical Center Three days / week 2008-2016 Internal Medicine Intern Selection Committee, New York Presbyterian Hospital – Weill Cornell Medical Center 2011 – 2014

Outpatient Hematology Attending for Cell Apheresis Service, New York Presbyterian Hospital – Weill Cornell Medical Center 1 month / year 2011 – 2016

Developer of the Outpatient Stem Cell Transplant Program, New York Presbyterian Hospital – Weill Cornell Medical Center, 2011 Inpatient Hematology Attending for the Bone Marrow Transplant Service, New York Presbyterian Hospital – Weill Cornell Medical Center 1 month / year 2008 – 2016 Inpatient Hematology Attending for the Malignant Hematology Service, New York Presbyterian Hospital – Weill Cornell Medical Center 1 month / year 2008 – 2015 Inpatient Hematology Attending for the Multiple Myeloma and Autologous Stem Cell Transplant Service, New York Presbyterian Hospital – Weill Cornell Medical Center 2 months / year 2015 – 2016 Inpatient Hematology Attending for the Bone Marrow Transplant Service University of Colorado – Anschutz Medical Campus 3 months / year 9/2016 – present


5

Outpatient Hematology Attending for the Blood Disorders Clinic University of Colorado – Anschutz Medical Campus 3 clinics (4 hours each) / week 9/2016 - present

Director of Inpatient Multiple Myeloma and Autologous Stem Cell Transplantation Service, New York Presbyterian Hospital – Weill Cornell Medical Center, 2015 - 2016 Clinical Director of Plasma Cell Disorders Program at the University of Colorado – Anschutz Medical Campus, September 2016-present Clinical Director of the Autologous Stem Cell Transplant Program at the University of Colorado – Anschutz Medical Campus, October 2016-present

Licensure and Board Certification: New York State Medical License, 4/29/05 – present Colorado State Medical License, 8/17/16 – present Drug Enforcement Agency, 1/31/04 – present Board Certified in Internal Medicine by The American Board of Internal Medicine; January 2005 - January 2015; recertification January 2015 – January 2025.

Board Certified in Hematology by the American Board of Internal Medicine; January 2008-2018; recertification October 2017-January 2028

Board Certified in Medical Oncology by the American Board of Internal Medicine; January

2008-2018; recertification October 2018-January 2028 Review and Referee Work Reviewer for the journal Transplantation, 2009 Reviewer for the journal Clinical Lymphoma and Myeloma, 2009 Reviewer for the journal Expert Opinion on Biological Therapy, 2009-2018 Reviewer for the British Journal of Hematology, 2010

Reviewer for the Health Review Board National SpR/SR Academic Fellowship Programme, Ireland, 2011

Reviewer for the journal Expert Opinion On Drug Metabolism & Toxicology, 2012-2013 Reviewer for the Journal of Medical Economics, 2012 Reviewer for the journal Drugs of Today, 2012 Reviewer for the journal Leukemia Research, 2013 Reviewer for the British Journal of Hematology, 2013 Reviewer for the journal Cancer Treatment Reviews, 2014 Special Guest Editor: Journal of Hematology & Transfusion, 2014 Reviewer for Cancer Letters, 2014-2018


6

Reviewer for Clinical Lymphoma, Myeloma & Leukemia, 2014-2018 Reviewer for Therapeutic Advances in Hematology, 2014-2018 Reviewer for Hematological Oncology, 2014 Reviewer for BioMed Central Hematology, 2015 Reviewer for Immunopharmacology and Immunotoxicology, 2016 Reviewer for BMC Hematology, 2016 Reviewer for Expert Opinion on Drug Safety, 2016 Reviewer for Annals of Hematology, 2016 Reviewer for Drugs, 2017 Reviewer for Cancer, 2017-present Reviewer for American Journal of Hematology, 2017

Reviewer for Frontline Medical Communications, Hematology-Oncology Board Review Manual, 2018

Reviewer for European Journal of Hematology, 2018 Reviewer for Computational and Structural Biotechnology Journal, 2018

Invited Presentations

International Myeloma Workshop Washington D.C. “Extended follow-up results of BiRD therapy: prolonged responses achieved” February 26, 2009 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY “Case presentation of multiple myeloma with audience participation” October 16, 2008 American Society of Hematology Annual Meeting Atlanta, GA “ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma” December 12, 2011 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY “New treatments and how best to use them in lymphoma and myeloma Presentation: Pomalidomide” October 21, 2011 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY “Session IV: Myeloma treatment presentation: Update on novel combinations for relapsed/refractory disease: Coming soon” October 25, 2012


7

American Society of Hematology Annual Meeting Atlanta, GA “ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma, An Update” December 9, 2012 Great Debates and Updates in Hematologic Malignancies New York, NY “Debate: Two vs Three Drugs in Multiple Myeloma” April 26, 2013 Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY “Debate: What is the best induction therapy in transplant-eligible patients?” October 24, 2013

Lymphoma and Myeloma: An International Congress of Hematologic Malignancies

New York, NY “Meet the Expert Panel” October 22,2014 “Induction therapies in transplant eligible patients” October 23, 2014


New York, NY “Debate: Is transplant a necessity or a choice: Focus on the necessity for CR and MRD” October 22, 2015


New York, NY “Monoclonal antibodies: A new wave for the future” October 13, 2016 “Meet the Expert Panel” October 14,2016

University of Colorado, American Society of Hematology 2016 Review Conference Update, Aurora, CO “Best of Myeloma at ASH 2016.” January 27, 2017 Leukemia & Lymphoma Society: 7th Annual Rocky Mountain Blood Cancer Conference, Aurora, CO “Amyloidosis” April 8, 2017


8

Lymphoma and Myeloma: An International Congress of Hematologic Malignancies New York, NY

“In the relapsed patient, what would be the ideal treatment?” October 26, 2017 “Meet the Expert Panel” October 27, 2017 Research & Innovation Conference, University of Colorado, Anschutz Medical Campus, Aurora, CO “Can We Reduce Cost of Multiple Myeloma Care Without Sacrificing Quality?” January 25, 2018 Leukemia & Lymphoma Society: 7th Annual Rocky Mountain Blood Cancer Conference, Aurora, CO “Amyloidosis” April 8, 2017 Leukemia & Lymphoma Society: 8th Annual Rocky Mountain Blood Cancer Conference, Aurora, CO “Myeloma for Patients and Caregivers” April 7, 2018 Leukemia & Lymphoma Society: 8th Annual Rocky Mountain Blood Cancer Conference, Aurora, CO “Myeloma for Health Care providers” April 7, 2018 Bone Marrow Transplant Infonet Conference, Aurora, CO “Meet the Myeloma Experts” April 29, 2018 Association of Community Cancer Centers: “Managing the toxicities of multiple myeloma treatment” November 1, 2018 US Oncology Network Annual Conference and Spring Pharmacy and Therapeutics Meeting, Orlando, FL “Treatment goals in Multiple Myeloma: Key Considerations for Older Patients.” April 6, 2019 American Office of Home Underwriters Annual Meeting, New Orleans, LA “Cutting Edge Cancer Treatments: Cutting Edge Immunotherapy.” April 30, 2019 Leukemia & Lymphoma Society: 8th Annual Rocky Mountain Blood Cancer Conference, Aurora, CO


9

“Prospects and Pitfalls in Multiple Myeloma: What Patients and Caregivers Need to Know” April 7, 2018

Teaching Record: Medical School

Weill Cornell Medical College Lecturer, Basis of Disease Course for 1st year medical students – “Plasma Cell Neoplasms” 2008-2016 Trinity School of Medicine St. Vincent and the Grenadines Lecturer – Oncology Course 10/11/07 – 10/18/07 St. George School of Medicine Lecturer – Oncology Course Grenada 4/22/08 – 4/25/08 Weill Cornell Medical College in Qatar Doha, Qatar Lecturer – Oncology Module March 30 – April 2, 2009 Weill Cornell Medical College Small Group Faculty Leader – “Coagulation” April 3, 2008 Weill Cornell Medical College Small Group Faculty Leader – “Hematologic Malignancies” April 7 2014; April 9, 2014

Weill Cornell Medical College Small Group Faculty Leader – “Antineoplastics” March 11, 2015

Weill Cornell Medical College / New York Presbyterian Hospital Key Clinical Faculty Member for the Hematology-Oncology Fellowship


10

Was involved in fellowship applicant screening and selection. Was also involved in developing overall curricula for hematology / medical oncology fellowship. 2010-2016 Weill Cornell Medical College Fellowship Program in Hematology and Oncology Course Director: Outpatient Malignant Hematology – updated the fellowship manual, organized outpatient hematology curriculum. 2012-2016 Ward and Clinic Teaching: Weill Cornell Medical College Outpatient Plasma Cell Disorders Clinic: Supervision and clinical evaluation of rotating internal medicine residents and hematology-oncology fellows; approximately 1 resident or fellow / month – 6 hours / week. 2008-2016 Weill Cornell Medical College Outpatient Hematology-Medical Oncology Fellows’ Clinic: Supervision and clinical evaluation of hematology-oncology fellows in continuity clinic; chemotherapy teaching. A variety of patients seen with both benign and malignant hematologic diseases, as well as a general oncology population. Approximately 1 clinic session of 4 hours / month. 2008-2016 New York Presbyterian Hospital Inpatient Bone Marrow Transplant, Malignant Hematology, and Multiple Myeloma / Autologous Stem Cell Transplant Services Supervision and clinical evaluation of rotating internal medicine residents and hematology-oncology fellows; approximately 2 residents or fellows / month – 3 months / year. University of Colorado - Anschutz Medical Campus Inpatient Bone Marrow Transplant Service Supervision and clinical evaluation of 2 advanced practice providers, occasionally 1 hematology or blood bank fellow, 1 pharmacist, occasionally 1 medical resident. – 3 months / year.

Academic Presentations

University of Connecticut Health Science Center West Hartford, CT Grand Rounds - “Multiple Myeloma in 2012: What you need to know” March 22, 2012


11

Fox Chase Cancer Center Philadelphia, PA

Grand Rounds - “Multiple Myeloma in 2012: What you need to know” September 13, 2012 Staten Island University Hospital Staten Island, NY

Grand Rounds - “Multiple Myeloma in 2012: What you need to know” November 12, 2013

Wyckoff Heights Medical Center Brooklyn, NY Grand Rounds - “Multiple Myeloma in 2015: What you need to know” July 12, 2015 University of Colorado, Hematology-Oncology Grand Rounds Grand Rounds - “Myeloma in 2016: What you need to know.” January 26, 2016 Oregon Health and Science University Grand Rounds - “Myeloma in 2016: What you need to know.” February 1, 2016 Dartmouth-Hitchcock Hospital / Norris Cotton Cancer Center Grand Rounds - “Myeloma in 2016: What you need to know.” March 15, 2016 University of Colorado Internal Medicine Clinicopathological Conference Faculty Discussant October 24, 2016 University of Colorado Internal Medicine Clinicopathological Conference Faculty Discussant December 16, 2016

University of Colorado, Anschutz Medical Campus Didactic Session for Hematology Fellows and Advanced Practice Providers

"Plasma Cell Disorders, but Mostly Myeloma." February 3, 2017

University of Colorado, Anschutz Medical Campus Didactic Session for Hematology Fellows and Advanced Practice Providers

"Treatment of Multiple Myeloma” March 3, 2017

University of Colorado, Anschutz Medical Campus


12

Didactic Session for Hematology Fellows and Advanced Practice Providers "New Drugs in Multiple Myeloma”

November 9, 2017 University of Colorado, Review of the 2018 American Society of Hematology Meeting Course director

Day long, CME course with multiple national experts on varied hematologic topics of interest including acute myeloma leukemia, multiple myeloma, lymphomas, and benign hematologic disorders. January 26, 2019 2019 US Oncology Annual Meeting, Orlando, FL “Treatment Goals in Multiple Myeloma: Key Considerations for Older Patients.” April 6, 2019

Mentorship:

1. Mentor for Adriana Rossi MD during her fellowship, current faculty at the Weil Cornell Myeloma Center: K30 Clinical Research Curriculum Award 2011, KL2 Clinical Research Scholars Award 2012, Scott Wadler Clinical Research Award 2013. Multiple publications in high impact journals. 2. Mentor for John Allan MD during his fellowship, current faculty in Weill Cornell Medical College; Hematology and Oncology: “Car-BiRD” protocol design and execution; presentation at Car-BiRD results at ASH 2013; stem cell mobilization analysis in conjunction with the laboratory of Dr. Monica Guzman. 3. Mentor for Peter Forsberg MD, during his fellowship and again as current faculty at University of Colorado in the Hematology division. Work included Ki67 analysis and impact in the treatment of newly diagnosed multiple myeloma, in conjunction with Scott Ely, director of the hematopathology fellowship program at WCMC. Recipient of International Myeloma Workshop Rising Star Award and Plenary Session Oral Abstract Presentation in Rome, Italy 2015. 4. Mentor for Jason Meadows MD, medical resident at University of Hawaii; now faculty at Memorial Sloan Kettering Hospital; production and publication of a review article on pomalidomide use in myeloma; manuscript production analyzing the role of multiple M-proteins in newly diagnosed multiple myeloma. 5. Mentor for Yulian Khagi MD, currently in hematology-oncology fellowship at UC San Diego: manuscript preparation reviewing the emergence of daratumumab in the treatment of relapsed and refractory myeloma. 6. Mentor for Isabel Preeshagul, current chief fellow in Hematology and Oncology at Long Island Jewish Medical Center: manuscript preparation reviewing the role of


13

autologous stem cell transplant in myeloma, in conjunction with Dr. Koen Van Besien (director of stem cell transplantation at NYPH/Cornell). 7. Mentor for Karie Runcie, currently an internist a Long Island Jewish Medical Center: manuscript preparation reviewing new chemotherapy regimens for upfront treatment of multiple myeloma. 8. Clinical mentor for Daniel Sherbenou, currently an assistant professor of medicine at University of Colorado, Anschutz Medical Campus. Mentored a successful NIH K award and multiple translational projects in myeloma. 9. Mentor for medical student Lyndsey Babcock (MD 2021), for her Mentored Scholarly Activity (MSA) project. We worked on providing clinical data for an International Myeloma Working Group Project in smouldering multiple myeloma. She also co-authored a clinical case report describing translational research that is ongoing in the basic science myeloma laboratory at UC Anschutz. 10. Clinical research mentor for Colt Williams, PGY2, for an elective research block during internal medicine residency. Project 1: Carfilzomib induction with lenalidomide and clarithromycin consolidation for multiple myeloma. Work resulted in a co-authored manuscripts. Project 2: Phase 1 study of omacetaxine in relapsed or refractory multiple myeloma. Work resulted in a IRB-approved clinical trial protocol and study initiation.

Grant Support: Pharmaceutical Contracts and Grants: Active: 1) Sponsor: Janssen Protocol Name: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation. PI: Tomer Mark Total Budget/Patient: $78,659.20 for patient on D-RVD arm and $53,779.72 for patient on RVD arm. Total budget to be determined by enrollment. Project ongoing from 10/2017 to present 2) Sponsor: Celgene


14

Protocol Name: Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study. PI: Tomer Mark, Percent effort: 10% Total Budget/Patient: $12,069/patient in phase 1, $10,074 in phase 2; total budget $444,974 Project ongoing from 2009-2017 3) Sponsor: Onyx / Celgene Protocol Name: A Phase II Study of Sequential Carfilzomib, Calrithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects with Newly Diagnosed Multiple Myeloma. PI: Tomer Mark, Percent effort: 30% Total Budget/Patient: $5,320/patient; total budget $310,240 Project ongoing from 2011-2017 4) Sponsor: Celgene Protocol name: Phase II study of Dexamethasone, Clarithromycin and pomalidomide for subjects with relapsed or refractory multiple myeloma PI: Ruben Niesvizky Role: Principal Protocol Coordinator / Sub-Investigator Total Budget/Patient: $7,514.50; total budget $415,102 Project ongoing from 2011 to present. Completed and Inactive Projects: 1)Sponsor: Celgene Protocol Name: Autologous Stem Cell Transplant with Pomalidomide (CC-4047®) Maintenance versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by the Tri-State Transplant Consortium. Co-PI: Tomer Mark (WCMC) and Sergio Giralt (MSKCC), Percent effort: 10% Total Budget/Patient: $9,044/patient; total budget $961,715


15

Project ongoing from 2011-2015 2) Sponsor: Pfizer / Celgene Protocol Name: A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (palbociclib) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. PI: Tomer Mark Total Budget/Patient: $2,165/patient; total budget $36,029 Project ongoing from 2013-2015, Percent effort: 30% Publications: Poster Presentations: (2009-2017 only) American Society of Hematology Meeting December 2009:

Niesvizky R, Ely S, Jayabalan S, Manco M, Singhal S, Crann M, Courtney R, DuFresne C, Wilner K, Chen I, Mark T, Leonard JP, Coleman M, DiLiberto M, Huang X, Chen-Kiang S. Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma. Mark T, Coleman M, Jayabalan D, Pearse R, Zafar F, Ely S, Manco M, Crann M, Leonard JP, Chen-Kiang S, Niesvizky R. T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma. Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Chen-Kiang S, Roy V, Coleman M, Hayman SR, Buadi F, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin(Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. Manco M, Mark T, Jayabalan D, Zafar F, Pearse R, Crann M, Leonard JP, Chen-Kiang S, Coleman M, Niesvizky R. Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.

American Society of Clinical Oncology Meeting June 2010:


16

Ruan J, Mark T, Allan J, Morrison J, Koirala A, Martin P, Coleman M, Lachs M, Niesvizky R, and Leonard JP. Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents. Mark T, Koirala A, Pearse RN, Zafar F, Jayabalan D, Leonard JP, Coleman M, Niesvizky R. An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.

International Society of Hematology Meeting October 2010:

Mark T, Koirala A, Pearse R, Pekle K, Zafar F, Coleman M, Niesvizky R. Clarithromycin Deepens Response in Patients with Multiple Myeloma at Plateau With Thalidomide Plus Dexamethasone. Mark T, Koirala A, Pearse R, Zafar F, Pekle K, Christos P, Coleman M, Niesvizky R. Clarithromycin Increases Dexamethasone Exposure in Multiple Myeloma. Mark T, Koirala A, Pearse R, Coleman M, Niesvizky R. Clinical Outcomes of Persons With Multiple M-Spikes at Initial Diagnosis in Multiple Myeloma.

American Society of Hematology Meeting December 2010:

Mark T, Rossi A, Pearse R, Coleman M, Bernstein D, Zafar F, Gergis U, Shore T, Niesvizky R. A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. Mark T, O'Loughlin J, Coleman M, Jayabalan D, Pearse R, Zafar F, Ely S, Manco M, Mignott P, Leonard J, Chen-Kiang S, Niesvizky. Updated Report of T-Bird (thalidomide, clarithromycin/ [Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma.

American Society of Bone Marrow Transplantation Tandem Meeting February 2011

Ward M, Mark T, Manco M, Stern J, O'Loughlin J, Shore T, Pearse R, Zafar F, Jayabalan

D, Skerrett D, Chen-Kiang S, Lane M, Niesvizky R. High-yield of CD34+ cells with bortezomib-based mobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients. Mark T, Niesvizky R, Gergis U, Pearse R, Mayer S, Feldman E, Shore, R. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant with Multiple Myeloma.


17

American Society of Clinical Oncology Meeting June 2011

Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Shore T, Pearse R, Leonard J, Chen-Kiang S, Coleman M, Niesvizky R. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma(MM). Kostakoglu L, Dingli D, Beksac M, Zamagni E, Mark T, Chari A, Elliott B, Lowe V, Ozkan E, Nanni C, Kucuk O, Fanti S, Coleman M, Jagannath S. Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).

American Society of Hematology Meeting December 2011

Mark T, Rodriguez M, Shah M, Quinn R, Campbell J, Abdullah R, Pearse R, Zafar F, Pekle K, Mignott P, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Gergis U, Roboz G, Ritchie E, Scandura J, Carlson K, Shore T, Mayer S, Mark T, Pearse R, Greenberg J, Cucrico T, ippoliti C, McKenna M, Feldman E. A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia. Mark T, Shah M, Rodriguez M, Quinn R, Pearse R, Zafar F, Pekle K, Mignott P, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Nievizky R. T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma. Mark T, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Coleman M, Feldman E, Shore T. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma.


Rossi A, Mark T, Rodriguez M, Shah M, Quinn R, Pearse R, Zafar F, Pekle K, Speaker S, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma. Kostakoglu L, Dingli D, Beksac M, Zamagni E, Mark T, Chari A, Elliott B, Lowe V, Ozkan E, Nanni C, Kucuk O, Fanti S, Coleman M, Jagannath S. Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).


18

American Society Of Hematology Meeting December 2012:

Huang X, Jayabalan D, Di Liberto M, Harvey J, Schinzel A, Mark T, Hussein M, Randolph S, Hahn W, Niesvizky R, and Chen-Kiang S. Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition.


Mark T, Allan J, Marano G, Rossi A, Pearse R, Zafar F, Tegnestam L, Pekle K, Jayabalan D, Coleman M, Ely S, MD, Niesvizky R. Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide /(Revlimid®), Dexamethasone) For Newly-Diagnosed Multiple Myeloma. Mark T, MD, Allan J, Boyer A, Rossi A, Pearse R, Zafar F, Pekle K, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma. Rossi A, Mark T, Wood K, Pearse R, Zafar F, Pekle K, Goldsmith S, Niesvizky R. PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma.


van Besien K, Liu H, Gergis U, Cushing M, Tsai S, Mayer S, Wickrema A, Stock W, Larson R, Shore TB, Odenike O, Pearse RN, Godley LA, Mark TM, Kline J, Cunningham JM, MD9, LaBelle J, Bishop MR, Artz A. Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. Mark TM, Forsberg P, Ouansafi I, Rossi AC, Pearse TN, MD, Pekle K, Perry A, Coleman M, Jayabalan D, Niesvizky R, Ely SA. The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma. Rhodes J, van Besien K, Liu H, MD, Gergis U, Tsai S, MD, Mayer S, Stock W, Larson RA, Shore TB, Odenike O, Pearse RN, M Godley LA, MD, Mark TM, Kline J, Bishop MR, Artz AS, MD, MS4Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50. Mark TM, MD, Schickner A, Allan JN, Rossi AC, Pearse RN, Tegnestam L, Pekle K, Perry A, Pognowski K, Jayabalan J, Coleman M, Niesvizky R. Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma.


19

Allan JN, Jayabalan D, Niesvizky R, Mark TM, Pearse RN, MD, Rossi AC, Tegnestam L, Hassane DC, Guzman M. Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF. Rossi AC, Aneja E, Boyer A, Jayabalan D, Mark TM, Pearse RN, Pekle K, Perry A, Coleman M, Niesvizky R. Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ, Uy GL, Hari PN, Zhang MJ, Huang J, Krishnan A, Mark TM, D'Souza A. Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. D'Souza A, Wirk B, Zhang MJ, Huang J, Krishnan A, Mark TM, Gasparetto CJ, Hari PN. Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study. Mark TM, Meadows JP, Koirala A, Jayabalan D, Niesvizky R. A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins.


Forsberg P, Mark TM, Yadlapati S, Rossi AC, Pearse RN, Pekle K, Perry A, Coleman M, Jayabalan D, Niesvizky R, Ely S. Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma. Mark TM, Boyer A, Yadlapati S, Rossi AC, Pearse RN, Pekle K, Perry A, Pogonowski K, Aneja E, Tegnestam L, Jayabalan D, Ely S, Coleman M, Huang X, Liberto M, Chen-Kiang S, Niesvizky R. CLAPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. Mark TM, Yadlapati S, Neglyad L, Bourke J, Jayabalan D, Rossi AC, Pearse RN, Perry A, Pekle K, Pogonowski K, Tegnestam L, Huang X, Liberto M, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma. Huang X, Jayabalan D, Liberto M, Chen Z, Schinzel AC, Ely S, Rossi AC, Pearse RN, Aneja E, Coleman M, Lane JM, Hahn WC, Mark TM, Niesvizky R, Chen-Kiang S. Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation. Cornell RF, Costa LJ, Kassim AA, Inns-Shelton R, Krishnan A, Mark T, Nieto Y, Gasparetto CJ, D'Souza A, Hari P, Zhang MJ, Huang J. Post-Transplant Therapy Is More


20

Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM).

United States and Canadian Academy of Pathology Meeting March 2016:

Ely, S, Tacha S, Forsberg P, Ouansafi I, Niesvizky R, and Mark T (2016). "Cost Effectiveness of Cell Proliferation vs. Cytogenetics for Risk Stratification in Multiple Myeloma." Laboratory Investigation 96: 343a-343a.

American Society for Blood and Marrow Transplantation Tandem Meeting February 2016

Cornell, RF, Bachanova V, D'Souza A, Ahn KW, Huang JX, Krishnan A, Gasparetto C, Nieto Y, Mark TM, and Hari PN. "Outcomes after Allogeneic Transplant for Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia (Lpl/Wm): A Center for International Blood and Marrow Transplant Research Analysis." Biol Blood Marrow Tr. 2016;22(3):S219-S19. Bourke J, Mark TM, Silberzweig J, Enriquez U, van Besien K, Herbert B, et al. Extracorporeal Apheresis Via AV Fistula in Multiple Myeloma Patients with End Stage Renal Disease. Biol Blood Marrow Tr. 2016;22(3):S443-S4.

European Hematology Association Meeting June 2016:

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark T, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P. Phase 3 Randomised Controlled Study of Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Castor. Haematologica. 2016;101:340-1.


Ely S, Forsberg P, Niesvizky R, Mark TM. Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM). J Clin Oncol. 2016;34(15).

European Society of Medical Oncology Meeting October 2016:

Weisel K, Palumbo A, Chanan-Khan A, Nooka AK, Spicka I, Masszi T, Beksac M, Hungria V, Munder M, Mateos MV, Mark TM, Spencer A, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Sonneveld P. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Ann Oncol. 2016;27.


21

American Society of Hematology December 2016:

Diamond, B, Rossi AC, Pearse RN, Jayabalan D, Perry A, Pekle K, Mark T, and Niesvizky R. "Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma." 2016; Blood 128, 2016;128(22). Forsberg PA, Rossi AC, Pearse RN, Perry A, Pekle K, Jayabalan D, Ely S, Coleman M, Allan JN, Niesvizky R, Mark T. Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). Kumar S, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min CK, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist UH, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Mahindra A, Hari P, Fraser R, Fei MW, Mark T, Nieto Y, D'Souza A. Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without. Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Nooka AK. Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Lonial S. Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma.

European Hematology Association Meeting June 2017:

Weisel K, Lentzsch S, Mateos MV, Hungria V, Munder M, Nooka A, Mark T, Quach H, Scott EC, Lee JJ, Sonneveld P, Casneuf T, Chiu C, Qin X, Amin H, Thiyagarajah P, Schecter JM, Qi M, Spencer A. Efficacy and Safety of Daratumumab, Bortezomib and Dexamethasone (Dvd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Updated Analysis of Castor. Haematologica. 2017;102:168-9.

Peer Reviewed Manuscripts:


22

1) Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, Ullu E. Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000. 2) Niesvizky R, Naib T, Christos P, Jayabalan D, Furst J, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse R, Ely S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Toxicity evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007 Sep;138(5):640-3. 3) Mark T, Niesvizky R. The treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory agents. US Oncol Disease. 2007.Vol 2:26-30. 4) Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, DeSancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Rambo A. Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7. 5) Niesvizky R, Jayabalan D, Christos P, Furst J, Naib T, Ely S, Jalbrzikowski J, Pearse R, Zafar F, Pekle K, Lent R, Mark T, Cho H, Shore T, Tepler J, Harpel J, Schuster M, Mathew S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin®[clarithromycin]/ Revlimid®[lenalidomide]/ dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2008 Feb 1;111(3):1101-9. 6) Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. 7) Mark T, Jayabalan D, Pearse R. et al. Atypical Serum Immunofixation Patterns are frequently associated with immunomodulatory therapy and herald complete response in multiple myeloma. British Journal of Hematology. 2008. Dec;143(5):654-60. 8) Mark T, Niesvizky R, Coleman M. The Novel Agents in Multiple Myeloma: An Exciting Saga. Cancer. 2008. Nov;115(2):236-42. 9) Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009. Jan;18(1):99-104. 10) Mark T, Coleman M, Niesvizky R. Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Asia-Pacific Journal of Oncology & Hematology. 2009;1(2):1-5. 11) Niesvizky R, Coleman M, Mark T. Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant. Oncology. 2010;24(3):14-21.


23

12) Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Cheng-Kiang S, Roy V, Coleman M, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, and Niesvizky R. Superiority Of Clarithromycin (Biaxin)-Lenalidomide-low-dose dexamethasone (BiRd) Versus Lenalidomide-low-dose Dexamethasone (Rd) As Initial Therapy for Newly Diagnosed Multiple Myeloma. Am J Hematol. 2010 Sep;85(9):664-9. 13) Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove J, Wright JJ, Chen-Kiang S and Sparano JA. Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan;117(2):336-42. 14) Cushing M, Kawaguchi K, Friedman KD, and Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012 Jul;52(7):1535-41 15) Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, and Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012 Apr;87(4):433-5. 16) Dimopoulos, M, Terpos E, Goldschmidt H, Alegre A, Mark T, and Niesvizky R. Treatment with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Renal Impairment. Cancer Treatment Reviews. 2012 Dec;38(8):1012-9. 17) Richardson PG, Mark T, and Lacy MQ. Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol. 2013 Jun 17. 18) Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Jan 8. 19) Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant. 2013 Feb 20. 20) Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME. Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clin Cancer Res. 2013 Mar 1. 21) Forsberg PA, Mark TM. Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncol. 2013 Jul;9(7):939-48.


24

22) Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul;19(7):1040-5. 23) Meadows JP, Mark TM. Management of Double-Refractory Multiple Myeloma. Curr Hematol Malig Rep. 2013 Dec;8(4):253-60. 24) Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 Feb 17. 25) Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. T-BiRD (thalidomide, clarithromycin, lenalidomide and dexamethasone) therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma. 2014 Feb 28. 26) Mark TM, Coleman M, Niesvizky R. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leuk Res. 2014 Mar 13. 27) Khagi Y, Mark TM. Potential Role of Daratumumab in the Treatment of Multiple Myeloma. Onco Targets Ther. 2014 Jun 18;7:1095-100. 28) Preeshagul IR, Van Besien K, Mark TM. Controversies in Multiple Myeloma: to Transplant or Not? Curr Hematol Malig Rep. 2014 Aug 22. 29) Storch E, Mark TM, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion. 2015 Mar 21. 30) Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Jul 3. 31) Runcie KD, Mark TM. Novel Induction Regimens in Multiple Myeloma. Curr Hematol Malig Rep. 2015 Aug 15. 32) Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of


25

chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug 24. 33) D’Souza A, Dispenzieri A, Wirk B, Zhang M-J, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter G, Robert, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology. 2015 Nov 10;33(32):3741-9. 34) Novikov A, Holzer H, DeSimone RA, Abu-Zeinah G, Pisapia DJ, Mark TM, Pastore RD. Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature. Case Reports in Oncological Medicine. 2015; 4. 35) Lee HC, Mark T, Shah J. Practical Approaches to Management of Dual Refractory Multiple Myeloma. Curr Hematol Malig Rep. 2016; Feb 22. 36) Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016; Feb 18. 37) Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Aug 2: S1083-8791(16)30223-3. 38) van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2016 Jun 23:1-10. 39) Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. 40) van Besien K, Koshy N, Gergis U, Mayer S, Cushing M, Rennert H, Reich-Slotky R, Mark T, Pearse R, Rossi A, Phillips A, Vasovic L, Ferrante R, Hsu YM, Shore T. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2016 Oct 27:1-3. 41) Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt


26

G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 Jan;23(1):60-66. 42) Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. 43) Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. 44) Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug 15;123(16):3141-3149. 45) Kumar SK, Dimopoulos M, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O’Donnell EK, Vij R, Lokhorst HM, van de Donk N, Min C, Mark T, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 16 June 2017. 46) Sherbenou DW, Mark TM, Forsberg P. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):545-554. 47) Ely S, Forsberg P, Ousansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve Patients. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):825-833. 48) Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K. Granulocyte Colony-Stimulating


27

Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biol Blood Marrow Transplant. 2017 Oct 20. pii: S1083-8791(17)30795-4. 49) Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. 50) Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2017 Nov 16. doi: 10.1038/leu.2017.331. [Epub ahead of print] 51) Mark TM. Incorporating monoclonal antibodies into the management of multiple myeloma. Clin Adv Hematol Oncol. 2017 Dec;15(12):919-922. 52) Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System shows the most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 Aug 21. pii: S1083-8791(18)30478-6. doi: 10.1016/j.bbmt.2018.08.013. [Epub ahead of print] PMID: 30142419 53) Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B8, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R24, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Sep 20. pii: haematol.2018.194118. doi: 10.3324/ haematol.2018.194118. 54) Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018 Nov 5. doi: 10.1002/cncr.31706. PMID: 30395359 55) Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller


28

T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2018 Dec 21. [Epub ahead of print] PubMed PMID: 30579965 56) Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 Jan 11;1-3. PubMed PMID: 30632821 57) Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019 Feb 10. doi: 10.1002/ajh.25435. [Epub ahead of print] PMID: 30740766 58) Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027. PMID: 30792190 Letters to the Editor: 1) Mark TM, Coleman M. It's Time to Take Clarithromycin Seriously in Multiple Myeloma. Acta Haematol 2016;135:101-102. 2) Mark TM, Pekle K. Clonal Plasma Cells Keep Strange Company. Leuk Lymphoma. 2016 Jan 4:1-2. Book Chapters: 1) Mark T, Pearse RN. Pathophysiology of Bone Disease in Multiple Myeloma. Myeloma Therapy: Pursuing the Plasma Cell. Edited by: S. Lonial. Humana Press, Totowa, NJ. December 2008. pp 435-454. 2) Ely S, Niesvizky R, Mark T. B-cell immunoproliferative disorders, including multiple myeloma and primary amyloidosis. Knowles’ Neoplastic Hematopathology, 3rd edition. Lippincott Williams & Wilkins. December 2013.


29

3) Mark T, Schechter GP. Plasma Cell Disorders. Wintrobe’s Atlas of Clinical Hematology, 2nd edition. Lippincott Williams & Wilkins. September 2017. Books: Chin O, Mark T. Love, Olivia. WestBow Press. February 2012.

CURRICULUM VITAE University of Colorado School …...2014-2016 Associate Professor of Medicine...

Documents

Transcript of CURRICULUM VITAE University of Colorado School …...2014-2016 Associate Professor of Medicine...